Clinical features and follow-up of pediatric patients hospitalized for COVID-19
Related Experiment Video
Updated: Nov 9, 2025

Nasal Brushing Sampling and Processing Using Digital High Speed Ciliary Videomicroscopy – Adaptation for the COVID-19 Pandemic
Published on: November 7, 2020
Feng Tang1, Wanjun Luo1, Xiaowen Wang1
1Wuhan Children's Hospital (Wuhan Maternal and Child Healthcare Hospital), Tongji Medical College, Huazhong University of Science & Technology, Wuhan, China.
Insights
This study followed pediatric COVID-19 patients, finding right lobe pneumonia and elevated creatine kinase-MB levels persisted one month post-discharge. These findings highlight potential long-term effects of coronavirus disease 2019 in children.
Area of Science:
- Pediatric Infectious Diseases
- Viral Pneumonia Pathogenesis
- Clinical Manifestations of COVID-19
Background:
- Coronavirus disease 2019 (COVID-19) has impacted global health, with pediatric cases requiring specific clinical attention.
- Understanding the clinical course and long-term sequelae in children is crucial for effective management.
Purpose of the Study:
- To summarize clinical features and 1-month follow-up observations of pediatric patients hospitalized with COVID-19.
- To analyze the association between lung involvement and clinical outcomes.
Main Methods:
- Retrospective analysis of 127 pediatric patients hospitalized with COVID-19.
- Inclusion of clinical data, serum SARS-CoV-2 IgG/IgM tests, RT-PCR, lung CT scans, and laboratory tests.
- 1-month follow-up assessments for clinical manifestations and laboratory markers.
Main Results:
- Right lobe pneumonia was observed in 22% of patients at 1-month follow-up.
- Persistently elevated serum creatine kinase (CK) and creatine kinase-myocardial band (CK-MB) levels were noted.
- Four patients retested positive for SARS-CoV-2 at follow-up.
Conclusions:
- Lung lobe involvement in COVID-19 correlates with the persistence of pneumonia, elevated CK-MB, and body temperature.
- Right lobe pneumonia and elevated CK-MB may be indicators of prolonged recovery in pediatric COVID-19 patients.
Objective:
This report summarizes the clinical features and 1-month follow-up observations for pediatric patients who were hospitalized with coronavirus disease 2019 (COVID-19) in Wuhan Women and Children's Hospital.
Methods:
The 1-month follow-up data included clinical manifestations and results from serum severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) IgG and IgM tests, reverse-transcription polymerase chain reaction (RT-PCR) for SARS-CoV-2, lung computed tomography (CT) scans, and laboratory tests.
Results:
Between January 20 and March 15, 2020, 127 patients aged 0-15 years were hospitalized for COVID-19 treatment, including 3 severe cases and 124 mild or moderate cases. The main therapies included inhalation of aerosolized interferon-α (122/127) and additional antiviral drugs (28/127). Among the 81 patients who had pneumonia at admission, 35 with right lobe pneumonia had the longest hospital stay (mean 14.5 ± 7 days); 17 with left lobe pneumonia had the highest creatine kinase (154 ± 106 U/L) and creatine kinase myocardial band (CK-MB, 43 ± 48 U/L) levels; and 29 with bilateral pneumonia had the highest white blood cell counts (8.3 ± 4 × 109 /L). Among the 46 patients who were successfully followed up 1 month after discharge, two notable findings were right lobe pneumonia in 22% (95% confidence interval [CI]: 11%-37%) of patients and persistently elevated serum creatine kinase and CK-MB levels. The median duration of elevated CK-MB was 45 days. The mean concentrations of serum SARS-CoV-2 IgG and IgM in 41 patients were 8.0 ± 7.5 and 98 ± 40 ng/ml, respectively. At follow-up, four patients retested positive for SARS-CoV-2.
Conclusions:
The involvement of different lung lobes in patients with COVID-19 was associated with variations in the persistence of pneumonia and elevation of CK-MB levels and body temperature.
More Related Videos
08:05Lung CT Segmentation to Identify Consolidations and Ground Glass Areas for Quantitative Assesment of SARS-CoV Pneumonia
Published on: December 19, 2020
09:36Halogenated Agent Delivery in Porcine Model of Acute Respiratory Distress Syndrome via an Intensive Care Unit Type Device
Published on: September 24, 2020
Related Concept Videos
Pneumonia IV: Management
Bacterial Pneumonia Treatment
For bacterial pneumonia, antibiotics serve as the cornerstone of therapy. Initial treatment often begins with empirical antibiotics, tailored to the anticipated causative organism and adjusted based on culture results. Key antibiotic choices include:
Pneumonia III: Complications and Assessment
COPD: Pathogenesis and Clinical Features
The primary cause for the onset of COPD is cigarette smoking and exposure to air pollution. These hazardous factors initiate a chain reaction within the lungs, resulting in chronic inflammation, damage to the airways, and a...
Pharmacokinetics in Pediatric Patients: Drug Excretion
Pneumonia I: Introduction
Risk Factors
Various factors influence the likelihood of developing pneumonia. Age plays a crucial role, with infants, children under two, and individuals over 65 at increased risk due to their...
Pneumonia II: Pathophysiology